Hanlan Liu

SVP, Early Pipeline and Nonclinical Development
Be Biopharma
Cambridge, Massachusetts, United States

Presentation(s):

• OC 11.3 - Development of BE-101, an autologous ex vivo precision gene engineered B cell medicine that produces active and sustained levels of factor IX for the treatment of hemophilia B

  Sunday, June 23, 2024
  10:00 – 10:15 ICT